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We broadly profiled DNA methylation in breast can-
cers (n  351) and benign parenchyma (n  47) for
correspondence with disease phenotype, using FFPE
diagnostic surgical pathology specimens. Exploratory
analysis revealed a distinctive primary invasive carci-
noma subclass featuring extreme global methylation
deviation. Subsequently, we tested the correlation be-
tween methylation remodeling pervasiveness and
malignant biological features. A methyl deviation in-
dex (MDI) was calculated for each lesion relative to
terminal ductal-lobular unit baseline, and group com-
parisons revealed that high-grade and short-survival
estrogen receptor–positive (ER) cancers manifest a
significantly higher MDI than low-grade and long-
survival ER cancers. In contrast, ER cancers display
a significantly lower MDI, revealing a striking epig-
enomic distinction between cancer hormone recep-
tor subtypes. Kaplan-Meier survival curves of MDI-
based risk classes showed significant divergence
between low- and high-risk groups. MDI showed su-
perior prognostic performance to crude methylation
levels, and MDI retained prognostic significance (P <
0.01) in Cox multivariate analysis, including clinical
stage and pathological grade. Most MDI targets individ-
ually are significant markers of ER cancer survival.
Lymphoid andmesenchymal indexes were not substan-
tially different between ER and ER groups and do not
explain MDI dichotomy. However, the mesenchymal
index was associated with ER cancer survival, and a
high lymphoid index was associated with medullarycarcinoma. Finally, a comparison between metastases
and primary tumors suggests methylation patterns are
established early and maintained through disease pro-
gression for both ER and ER tumors. (Am J Pathol
2011, 179:55–65; DOI: 10.1016/j.ajpath.2011.03.022)
Breast cancer is a heterogeneous disease, manifesting
variation at the clinical, biological, histopathological, and
molecular levels. Profiling studies1,2 of gene expression
and DNA copy number have identified molecular markers
that can be used to distinguish clinically relevant tumor
subtypes. DNA methylation analysis is emerging as a
promising avenue for cancer classification; several stud-
ies3–7 point toward the potential for DNA methylation mark-
ers to identify distinct breast cancer phenotypes using can-
didate gene measurements and microarray analyses. As a
robust biomarker conserved in routinely processed clinical
specimens, DNA methylation is amenable to high-through-
put microarray-based discovery,8,9 providing a justification
for translational epigenotype-phenotype correlation in rou-
tine breast cancer pathological samples.
In the current study, we present a large-scale DNA
methylation analysis of primary invasive breast cancers
for deviation from the epigenetic state of the normal mam-
mary terminal ductal-lobular unit (TDLU). The TDLU is the
structural and functional unit of the mammary gland and
is generally considered the origin of breast carcino-
mas.10–13 In addition to providing a normal tissue epige-
netic baseline, the TDLU profile defined by DNA methyl-
ation targets invariant among numerous unrelated
patients permits filtration of array signals potentially aris-
ing from neutral genetic and epigenetic polymor-
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paraffin embedded (FFPE) pathological samples for bio-
marker discovery provides multiple unique benefits, in-
cluding an indication of potential biomarker applicability
to clinical practice.15
Contributions to measurements of cancer versus nor-
mal tissue epigenetic deviation may arise from both
within and outside the cancer cell nucleus. Intrinsic to the
cancer cell, de novo methyltransferase activity may gen-
erate divergent epialleles; not to be overlooked, faithful
maintenance methylation of conserved cell lineage–spe-
cific marks,5 coupled with malignant cell population en-
richment, could also manifest as differential methylation
between benign and cancer tissues. Meanwhile, cancer-
lesion epigenetic distinctions may be extrinsic to the can-
cer cell, arising from characteristic microanatomical em-
bedding of benign elements among cancer epithelial
cells that often determine histopathological classifica-
tion.16,17 For example, the microarchitecture of breast
medullary carcinoma displays syncytial cords of high-
grade malignant epithelial cells interwoven with channels
of benign lymphoid cells18,19; and the subtype-specific
molecular signature of the lesion will derive from both
compartments. By contrast, nonspecific heterogeneity
across biological subclasses may arise from benign
glandular and inflammatory elements and possibly iatro-
genic effects (ie, needle-core-biopsy–related changes).
Therefore, microscopy-based histological control and mo-
lecular quantification of constituent benign lymphoid and
mesenchymal epialleles may be beneficial for understand-
ing cancer tissue differential methylation signatures.
Subsequent to primary invasive tumorigenesis, the fi-
delity of maintenance and de novo DNA methylation dur-
ing disease progression is incompletely understood. Ar-
chival pathological specimens provide an opportunity to
compare primary tumors with longitudinal recurrences to
probe the status of these processes. Thus, finally, in our
study, we compare primary tumors with matched longi-
tudinal recurrences to obtain a global snapshot of the
methylome at different tumor stages and to investigate
the stability of DNA methylation patterns during disease
evolution.
Materials and Methods
Samples
FFPE breast cancer (n  351), benign breast TDLU (n 
32), reactive lymph node (n  9), and benign mesen-
chyme (fibromuscular tissue, n  5) samples were re-
trieved from the pathology department archives of Sub-
urban Hospital, Bethesda, MD (Table 1 and Figure 1). To
reduce case selection bias, we included all available
archival breast cancers from a consecutive 2-year period
in the analysis. Available clinical registry data included
cancer stage, follow-up interval, and time to distant re-
currence. Survival analyses were based on the end point
of distant recurrence. Specimens and corresponding
clinical data were deidentified according to the NIH Of-
fice of Human Subjects Research policy.Review and Processing of Specimen
Pathological Features
Histological sections were reviewed by a pathologist
(J.K.K.) for characteristic pathological features and
scored for cancer grade according to the Nottingham
system.20 The region of characteristic tumor histological
Table 1. Patient and Sample Characteristics
Characteristics by type of tissue No. affected
Breast carcinoma 351
Primary invasive breast carcinoma 312
Age at primary diagnosis (median,
60 years) (years)
50 76
50–69 151
70 82
NA 3
ERS
ER 249
ER 49
NA 14
Pathological grade (NHG)
1 (Low) 85
2 (Intermediate) 133
3 (High) 94
Clinical stage
I 130
IIA 60
IIB 35
IIIA 9
IIIB 14
IV 9
NA 55
Survival status
ER
Failure† (median, 2.5 years) 39
Censor‡ (median, 8 years) 118
NA 92
ER
Failure† (median, 1.8 years) 19
Censor‡ (median, 8 years) 11
NA 19
Molecular subtype comparisons*
Basallike status for ER cancers
Basallike 16
Not basallike 8
Ki-67 low vs high ER cancers
High 32
Low 47
Her-2 status for ER cancers
Amplified 23
Not amplified 104
Her-2 status for ER cancers
Amplified 10
Not amplified 21
Metastatic breast carcinoma 30
Invasive breast carcinoma NOS 9
Benign tissues 46
Mammary TDLU 32
Muscle tissue (female) 5
Benign lymph node (female) 9
There were 397 total lesions and tissues.
*Tested and informative samples in each category.
†Failure indicates subsequent distant breast cancer metastasis.
‡Censor indicates 7 years’ follow up with no distant metastasis.
ERS, ER status; NA, not annotated; NHG, Nottingham histological
grade; NOS, not otherwise specified.features with maximal tumor-cell fraction was marked on
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dissected from the homologous region of the corre-
sponding FFPE tissue block using a 1- to 2-mm needle
micropunch (J.K.K.). Similarly, benign TDLUs, lymph
nodes, and mesenchymal muscle and fibrous elements
were needle dissected from paraffin blocks under histo-
logical guidance. Tissue cores were lysed by incubation
at 65°C for 2 to 3 days in 200 L of FFPE tissue lysis
solution (160 L of Qiagen ATL  20 L of Qiagen
proteinase K  20 L of Dako target retrieval solution),
and lysates were processed to yield 1 to 2 g of bisulfite-
modified DNA using the EZ DNA methylation kit (Zymo
Research, Irvine, CA). The yield of bisulfite-converted
DNA was measured by Nanodrop (ThermoScientific, Wil-
mington, DE).
Immunophenotyping
From available paraffin blocks with residual tumor, adja-
cent 2-mm cores to those used for methylation profiling
were taken to construct TMAs for immunophenotyping.
TMA slide sections were immunostained for estrogen re-
ceptor (ER), progesterone receptor, Her-2, CK5/6, pan-CK,
Ki-67, and epidermal growth factor receptor in a diagnostic
pathology laboratory using a Ventana autostainer (Ventana
Medical Systems, Inc., Tucson, AZ) with antibody clones
SP1, 1E2, 4B5, D5/16B4, AE1AE3, 30-9, and 2-18C9, re-
spectively. The cutoff for Ki-67 low versus high proliferative
index was positive staining of 10% cancer cell nuclei.21,22
The basallike immunophenotype was determined by a five-
marker panel.23
DNA Methylation Arrays
Bisulfite-converted DNA, 250 ng, was assayed using the
GoldenGate Cancer Panel I methylation assay (Illumina,
Inc., San Diego, CA), as previously described.24,25
Briefly, this assay measures DNA methylation at 1505
distinct CpG targets distributed among 807 genes. Sam-
ple target methylation  values that approximate percent-
age methylation within the sample homogenate were ex-
tracted in BeadStudio (Illumina, Inc.) from raw Cy3 and
Cy5 signal intensities. Samples that did not pass array
internal controls were excluded. The lesion  is the aver-
Figure 1. Representative photomicrographs of tissues used in the study.
Top: TDLU, reactive lymph node, and fibromuscular tissue. Bottom: Low-,
intermediate-, and high-grade primary invasive breast carcinomas. (Images
are shown from left to right.)age  of any samples that were technical replicates (DNAor needle cores) derived from a single patient lesion.
Methylation  data are provided in Supplemental Table
S1 (available at http://ajp.amjpathol.org). Methylation data
may also be retrieved from Gene Expression Omnibus.
Data Analysis
Dynamic data exploration and discovery analyses were
performed using Qlucore Omics Explorer version 2.1
(Qlucore AB, Lund, Sweden), as follows. The 1505 array
target methylation  values from 32 TDLU and 312 pri-
mary carcinoma lesions were extracted from BeadStudio
and imported to QOE. Data normalization was set as
follows: mean  0 and variance  1; the hierarchical
clustering module was set to maximum linkage, and the
variance filter was dynamically tuned while observing sam-
ple and variable clustering. The variance was set to 0.5 to
yield the set of 242 target variables shown in Figure 2A.
Target methyl deviation was calculated as the methyl-
ation  difference between sample and TDLU baseline.
The baseline target  is the TDLU group average  from
32 different individuals.
Target Methyl Deviation abs(lesionbaseline), where
baseline avgTDLU.
Figure 2. Exploratory data analysis and observation of the methyl-deviator
subclass. A: Hierarchical clustering of target methylation  of benign breast
parenchymal TDLU (n 32) and primary breast cancers (n 312) (242 CpG
targets, see Material and Methods) segregates methyl-deviator breast cancer
subgroup from TDLU and other breast cancers. Green, black, and red heat
map shades correspond to target methylation  continuous scores of 0 to 0.5
to 1. B: Box plot summary statistics comparing the distribution of MDI_109 in
various clinicopathological breast cancer groups. NHG indicates Nottingham
histological grade; ERS, ER status; short survival, primary cancers later fol-
lowed by distant recurrence; and long survival, primary cancers not followed
by distant recurrence, with at least 7 years of follow-up.
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the methyl deviation index (MDI) of each lesion:
MDI abs(lesionbaseline).
Of 1505 array targets, 237 had a baseline variance 0.1,
and these targets were excluded from calculations of
MDI that implement a baseline uniformity filter. Target
MDI rank from highest to lowest is the SD of the target
within the group. For example, the top 100 MDI targets in
the ER cancer group are the 100 targets with the great-
est SD in that group.
Alternative to MDI, the methylation  index was calcu-
lated as the sum of all target methylation levels within the
lesion without reference to a baseline:
Methylation  Index lesion.
The performances of multiple different arbitrary cancer
variance cutoffs for MDI-based survival prognostication
were compared using receiver operating characteristic
(ROC) area under the curve (AUC) analysis, as was the
performance of MDI versus methylation  index.
The statistical significance (P values and false-discovery-
rate–corrected Q scores) of MDI target measures between
long- versus short-survival ER breast cancers was calcu-
lated by two-group comparison of array CpG target vari-
Table 2. Cox Multivariate Regression Analysis of Prognostic Fact
Prognostic variable
Univariate
HR 95% CI
LI_59
Low 1
High 0.966 0.5155–1.81
MI_44
Low 1
High 0.337 0.1679–0.6781
MDI_109
Low 1
Intermediate 6.643 1.527–28.9
High 13.2 3.091–56.32
HER2
 1
 5.313 1.356–20.82
PR
 1
 0.49 0.1066–2.248
Ki-67
Low 1
High 4.715 0.9141–24.32
Histologic grade
1 1
2 1.929 0.8388–4.438
3 4.58 1.893–11.079
Age at diagnosis (years)
50 1
50–69 0.757 0.3493–1.64
70 0.864 0.3671–2.036
Stage
I and II 1
III and IV 7.447 3.685–15.05
*Variables included in the multivariate analysis were significant by un
†By Wald’s test.
CI, confidence interval; HR, hazard ratio; PR, progesterone receptor; —, didables using analysis of variance in QOE. The MDI_72sig
refers to the intersection of statistically significant survival
targets between long- and short-survival ER cancers (P
0.05), with the top 100 MDI targets in the ER cancer group.
To calculate the lymphoid index (LI), statistically sig-
nificant lymphoid-specific methyl markers relative to
TDLU (analysis of variance, P  0.05) were identified in
QOE. The input target variables were the 1268 conform-
ing TDLU targets (variance 0.1, as previously indi-
cated), and the samples were the 32 TDLU and the 9
female lymphoid tissues. Next, the LI_59 was calculated
for each primary cancer lesion after setting the variance
filter to 0.5 (to enrich for lymphoid-specific markers of
highest contrast) and dividing by 59, the number of tar-
gets in the resulting cassette:
LI (1 [abs(lesionlymphoid)] ⁄ 59).
The same concept was used to calculate the lesion mes-
enchymal index (MI) by summing mesenchyme-specific
methylation markers relative to TDLU:
MI (1 [abs(lesionmesenchymal)] ⁄ 44).
MDI, LI, and MI were treated as continuous variables and
were not stratified or discretized for ROC and pairwise
analyses. For the Kaplan-Meier survival analysis and Cox
Breast Carcinoma
Multivariate*
P value† HR 95% CI P value†
0.9141 —
— —
— —
0.002282 0.45764
1
0.74 0.33445–1.6377
0.001 0.0198
1
3.955 0.8687–18.01
7.503 1.6172–34.812
0.0165 —
— —
— —
0.358 —
— —
— —
0.0639 —
— —
— —
0.002289 0.188
1
1.116 0.4388–2.84
2.115 0.7793–5.741
0.7759 —
— —
— —
— —
0.001 0.001
1
4.363 2.0429–9.316
analysis and had data available for 10% of samples.ors for


ivariatenot meet the criteria for inclusion in multivariate analysis.
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invasive carcinomas and 7 years of follow-up (n  157)
were assigned to low-, middle-, and high-risk groups
based on MDI_109 rank (bottom, 30%; middle, 40%; and
top, 30%; respectively) and low- and high-risk groups
based on MI_44 and LI_59 rank (bottom, 50%; and top,
50%; respectively).
Box plot graphs, ROC calculations, and survival analyses
were performed using SigmaPlot11.2 (Systat Software, Inc.,
Chicago, IL) and R. Heat plots were generated in QOE.
Target significance for ER cancer survival (P values and Q
scores) was measured in QOE using analysis of variance.
Results
The methylation array profiles of 351 individual breast can-
cers and 46 noncancer tissues were included in the analy-
sis (Table 1 and Figure 1; see also Supplemental Table S1
at http://ajp.amjpathol.org). Dynamic data exploration of 312
primary invasive carcinomas and 32 TDLUs yielded 242
CpG target variables when the variance filter was tuned to
0.5. Hierarchical clustering revealed an out-group compris-
ing roughly 25% of cancers and manifesting maximal devi-
ation from baseline (Figure 2A). Target deflections from
baseline TDLU included both hypomethylations and hyper-
methylations, and the out-group was subsequently referred
to as the methyl-deviator group (Figure 2A). Annotation of
the clustered samples for ER status and Nottingham histo-
logical grade further suggested that the deviator out-group
is substantially enriched for high-grade ER cancers (Fig-
ure 2A). The least methyl-deviant cancers form a neighbor-
ing branch to TDLU and appear to be enriched for ER
cancers (Figure 2A).
Subsequently, we calculated an MDI for each sample
to use as a metric in group comparisons and survival
analyses. The MDI is calculated as the global sum of
target methyl deviations in a cancer relative to TDLU
baseline, for all targets that meet generic TDLU homoge-
neity and cancer heterogeneity variance thresholds. By
summing the absolute values of target methylation differ-
ence between a cancer sample and the baseline, both
positive and negative deflections from baseline positively
contribute to the MDI score. The MDI captures both the
amplitude and frequency of methyl deviation across the
cancer genome, while suppressing signals from neutral
epigenetic polymorphisms. In our initial comparative
analysis of MDI across various sample groups (Figure
2B), the baseline TDLU variance filter was set to 0.1,
whereas the cancer filter was set to 0.7, yielding an
overlap set of 109 CpG targets (MDI_109) distributed
among 85 discrete genes.
Summary statistics of MDI_109 values in clinically rel-
evant cancer subclasses are shown in Figure 2B. This
analysis confirmed the impression from the hierarchical
clustering that ER and ER cancer groups manifest
significant differences in global methylation reprogram-
ming. Notably, ER cancers have a greater MDI (P 
0.001), whereas the ER cancers are the most normal, as
in this parameter. Thus, the data exploration revealed
significant contrast in global deviation between ER andER tumors. Coupled with clinical and biological insight
that typically regards ER and ER cancers as distinct
entities, ER and ER groups were subsequently treated
separately for further clinicopathological correlation of
methyl deviation. The analysis focused on ER cancers
revealed a significantly higher MDI among tumors with
high-grade histological features and a poor prognosis
Figure 3. A: ROC curves demonstrate prognostic performance of several vari-
ance cutoffs in the calculation of the MDI. The MDI is the summation of target
differences from TDLU baseline for targets meeting tunable cancer heterogeneity
and baseline homogeneity cutoffs. The methylation  index (MI) is derived
solely from summation of array target methylation measures without refer-
ence to baseline. ER_MDI and ER_MI curves show superior performance
of MDI to MI for ER cancer prognostication. ER_MDI_72SIG shows a
modest increase to AUC by adding a statistical significance filter to top 100
MDI targets. ERU_MI_1505 (AUC  0.49) indicates the prognostic perfor-
mance on primary carcinomas unselected for hormone receptor status and
shows that failure to evaluate methyl deviation in ER and ER cancers
separately severely undermines MDI-based prognostication. A within the
figure indicates AUC. B: Kaplan-Meier plot shows a statistically significant
survival difference between low-, intermediate-, and high-risk distant me-
tastasis groups, defined by MDI. P  0.01 for all group comparisons.
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based on Ki-67 staining was correlated with a higher
MDI, with borderline significance (P  0.06). We did not
observe a correlation between MDI and Her-2 amplifica-
tion status of ER cancers (P  0.9).
Tuning of the cancer and baseline variance cutoffs
was performed to include between 3.5% (MDI_53) and
85% (MDI_1268) of array targets in the MDI calculation
(Figure 3A). These adjustments to variance cutoffs had
little effect on the performance of MDI as a prognostic
metric. For example, the ROC AUC for MDI-based prog-
Table 3. MDI_109 Targets Ranked by Statistical Significance
Target ID P value Q value 
IRAK3_P13_F 0.000 0.000 0.3
FES_P223_R 0.000 0.000 0.2
IRAK3_P185_F 0.000 0.000 0.2
IHH_E186_F 0.000 0.000 0.2
CSPG2_E38_F 0.000 0.000 0.2
FES_E34_R 0.000 0.000 0.2
IRAK3_E130_F 0.000 0.000 0.2
GSTP1_seq_38_S153_R 0.000 0.000 0.2
P2RX7_E323_R 0.000 0.000 0.2
PRKCDBP_E206_F 0.000 0.000 0.2
TGFB2_E226_R 0.000 0.000 0.2
DLK1_E227_R 0.000 0.000 0.2
HTR1B_P222_F 0.000 0.000 0.2
MMP14_P13_F 0.000 0.000 0.1
COL1A2_E299_F 0.000 0.000 0.2
COL1A2_P48_R 0.000 0.000 0.2
MYOD1_E156_F 0.000 0.000 0.1
STAT5A_E42_F 0.000 0.000 0.1
EPO_E244_R 0.000 0.000 0.2
TBX1_P885_R 0.000 0.000 0.2
GSTP1_P74_F 0.000 0.000 0.1
EYA4_E277_F 0.000 0.000 0.1
WNT2_P217_F 0.000 0.000 0.1
ASCL2_E76_R 0.000 0.001 0.1
SFRP1_P157_F 0.000 0.001 0.2
PLAU_P176_R 0.000 0.001 0.1
GSTP1_E322_R 0.000 0.001 0.2
ST6GAL1_P528_F 0.000 0.001 0.1
ADAMTS12_P250_R 0.000 0.001 0.1
PGF_P320_F 0.001 0.002 0.1
SFRP1_E398_R 0.001 0.002 0.1
WT1_E32_F 0.001 0.003 0.1
ISL1_E87_R 0.001 0.003 0.1
PALM2-AKAP2_P420_R 0.001 0.003 0.1
VIM_P811_R 0.001 0.003 0.1
PDGFRB_E195_R 0.001 0.004 0.1
KIT_P405_F 0.002 0.004 0.1
SLIT2_E111_R 0.002 0.004 0.1
PAX6_P50_R 0.002 0.005 0.1
PDGFRB_P343_F 0.002 0.005 0.1
NTSR1_P318_F 0.002 0.005 0.1
MDR1_seq_42_S300_R 0.002 0.005 0.1
ISL1_P379_F 0.002 0.005 0.1
ADCYAP1_P398_F 0.003 0.007 0.1
TMEFF2_E94_R 0.003 0.007 0.1
GABRB3_E42_F 0.003 0.007 0.1
CCNA1_P216_F 0.003 0.007 0.1
TPEF_seq_44_S88_R 0.004 0.008 0.1
TMEFF2_P152_R 0.004 0.009 0.1
PTGS2_P308_F 0.005 0.011 0.1
EVI1_E47_R 0.006 0.012 0.1
CCND2_P898_R 0.006 0.013 0.1
GSTM2_E153_F 0.007 0.013 0.1
LYN_E353_F 0.007 0.014 0.1
GAS7_E148_F 0.007 0.014 0.12nosis is approximately 0.78 (Figure 3A), whether the can-
cer variance is titrated to be more target inclusive
(MDI_1268: variance  0.0, AUC  0.78) or target re-
strictive (MDI_53: variance  0.8, AUC  0.78). More-
over, all MDI target sets were significantly prognostic for
ER cancer survival (P  0.001). In contrast to this rela-
tive insensitivity to adjusting the variance filters, prognos-
tic performance is substantially undermined when the
TDLU baseline reference is removed and crude methyl-
ation levels are summed, as the AUC decreases to 0.60
(Figure 3A, MBI_1505). Even more important, failure to
Target ID P value Q value 
TERT_P360_R 0.007 0.014 0.12
EVI1_P30_R 0.008 0.015 0.12
APC_P280_R 0.009 0.016 0.13
CD9_P504_F 0.010 0.017 0.12
CHGA_E52_F 0.014 0.026 0.12
MYH11_P22_F 0.015 0.026 0.12
COL18A1_P494_R 0.017 0.030 0.10
BMP3_P56_R 0.021 0.036 0.10
PDGFRA_P1429_F 0.021 0.036 0.11
SLIT2_P208_F 0.022 0.036 0.11
DIO3_P674_F 0.028 0.045 0.10
SOX1_P294_F 0.028 0.045 0.10
ONECUT2_P315_R 0.029 0.045 0.10
ASCL2_P360_F 0.029 0.045 0.10
LOX_P313_R 0.033 0.052 0.10
IGF2_E134_R 0.034 0.053 0.10
CCND2_P887_F 0.035 0.053 0.10
EGFR_E295_R 0.035 0.053 0.09
DBC1_P351_R 0.036 0.053 0.10
SLC22A3_E122_R 0.040 0.058 0.11
TWIST1_E117_R 0.044 0.062 0.10
ETV1_P235_F 0.044 0.062 0.10
SCGB3A1_E55_R 0.045 0.062 0.11
FABP3_E113_F 0.053 0.073 0.09
HHIP_E94_F 0.055 0.075 0.08
DAPK1_P10_F 0.060 0.080 0.09
WT1_P853_F 0.066 0.087 0.09
SMO_P455_R 0.075 0.099 0.07
NGFB_E353_F 0.082 0.106 0.09
NPY_P295_F 0.112 0.144 0.09
MOS_E60_R 0.120 0.152 0.08
HS3ST2_P171_F 0.123 0.154 0.07
MYBL2_P354_F 0.153 0.190 0.06
DAPK1_P345_R 0.180 0.222 0.07
ISL1_P554_F 0.214 0.261 0.06
PAX6_E129_F 0.217 0.262 0.05
MME_P388_F 0.221 0.263 0.06
KIT_P367_R 0.246 0.290 0.05
HDAC9_E38_F 0.284 0.332 0.04
ONECUT2_E96_F 0.298 0.343 0.04
RASSF1_P244_F 0.300 0.343 0.05
RASSF1_E116_F 0.381 0.433 0.05
BMP6_P163_F 0.404 0.454 0.04
NRG1_P558_R 0.412 0.458 0.04
AGTR1_P154_F 0.535 0.579 0.03
HOXB13_P17_R 0.595 0.635 0.02
FLI1_P620_R 0.597 0.635 0.02
EPHB1_P503_F 0.670 0.706 0.02
NEFL_P209_R 0.677 0.707 0.02
CDH13_E102_F 0.687 0.711 0.02
HS3ST2_E145_R 0.757 0.777 0.01
DLC1_E276_F 0.836 0.851 0.01
IGFBP3_P423_R 0.884 0.892 0.01
MYBL2_P211_F 0.919 0.919 0.004
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shifts the AUC to 0.49, totally effacing the prognostic
performance of MDI. Thus, we find the following: counting
cancer hypomethylations as positive contributors to methyl-
deviance computation has a substantial positive impact for
methylation-based prognostication; and it is essential to
Table 4. LI_59 and MI_44 Targets and Their Statistical Significan
LI_59
Target ID P value Q value 
AFF3_P122_F 0.0000 0.0000 0.48
AXL_P223_R 0.0000 0.0000 0.43
BLK_P14_F 0.0000 0.0000 0.35
C4B_E171_F 0.0000 0.0000 0.42
CARD15_P302_R 0.0000 0.0000 0.38
CD2_P68_F 0.0000 0.0000 0.66
CD86_P3_F 0.0000 0.0000 0.41
DDIT3_P1313_R 0.0000 0.0000 0.53
DDR1_P332_R 0.0000 0.0000 0.36
DLC1_E276_F 0.0000 0.0000 0.39
EPHA2_P203_F 0.0000 0.0000 0.41
EPHA2_P340_R 0.0000 0.0000 0.39
EVI2A_E420_F 0.0000 0.0000 0.40
EVI2A_P94_R 0.0000 0.0000 0.66
EYA4_P794_F 0.0000 0.0000 0.60
GFI1_P208_R 0.0000 0.0000 0.37
GJB2_P931_R 0.0000 0.0000 0.44
GRB7_E71_R 0.0000 0.0000 0.42
HCK_P858_F 0.0000 0.0000 0.64
HGF_E102_R 0.0000 0.0000 0.47
HLA-DPA1_P28_R 0.0000 0.0000 0.40
HOXA11_P698_F 0.0000 0.0000 0.50
HOXA5_P1324_F 0.0000 0.0000 0.42
HOXA9_P1141_R 0.0000 0.0000 0.58
HPN_P374_R 0.0000 0.0000 0.49
IGF1_E394_F 0.0000 0.0000 0.35
IL18BP_P51_R 0.0000 0.0000 0.56
IL1RN_P93_R 0.0000 0.0000 0.43
LAT_E46_F 0.0000 0.0000 0.64
LEFTY2_P561_F 0.0000 0.0000 0.34
LIG3_P622_R 0.0000 0.0000 0.39
LTA_E28_R 0.0000 0.0000 0.77
LTA_P214_R 0.0000 0.0000 0.60
LTB4R_E64_R 0.0000 0.0000 0.42
MMP14_P13_F 0.0000 0.0000 0.55
MT1A_P600_F 0.0000 0.0000 0.59
NPR2_P618_F 0.0000 0.0000 0.43
OGG1_E400_F 0.0000 0.0000 0.60
OSM_P188_F 0.0000 0.0000 0.66
OSM_P34_F 0.0000 0.0000 0.47
PTPN6_P282_R 0.0000 0.0000 0.35
RARRES1_P426_R 0.0000 0.0000 0.55
RHOH_P121_F 0.0000 0.0000 0.74
RIPK3_P124_F 0.0000 0.0000 0.48
RUNX3_E27_R 0.0000 0.0000 0.54
RUNX3_P247_F 0.0000 0.0000 0.70
RUNX3_P393_R 0.0000 0.0000 0.60
SEPT5_P441_F 0.0000 0.0000 0.51
SEPT9_P374_F 0.0000 0.0000 0.46
SNCG_P98_R 0.0000 0.0000 0.46
THBS2_P605_R 0.0000 0.0000 0.58
TNFSF8_E258_R 0.0000 0.0000 0.67
TNFSF8_P184_F 0.0000 0.0000 0.68
TNK1_P221_F 0.0000 0.0000 0.43
TRIP6_P1274_R 0.0000 0.0000 0.37
TSC2_E140_F 0.0000 0.0000 0.61
VAMP8_P114_F 0.0000 0.0000 0.37
VAV1_P317_F 0.0000 0.0000 0.37
WNT10B_P823_R 0.0000 0.0000 0.44perform MDI-based prognosis separately for ER and ER
cancers. Kaplan-Meier survival analysis further showed a
significant difference in time to distant recurrence between
MDI-low and MDI-high ER cancers (Figure 3B).
Because MDI target summation captures methyl devi-
ation in cancer as a global process, it does not determine
MI_44
Target ID P value Q value 
CVR1C_P363_F 0.0032 0.0043 0.14
OC3_P890_R 0.0094 0.0115 0.13
PC_P14_F 0.0038 0.005 0.15
POA1_P261_F 4E-05 9E-05 0.2
RHGDIB_P148_R 6E-06 2E-05 0.26
SCL1_P747_F 2E-06 9E-06 0.24
RCA1_P835_R 0.0016 0.0023 0.17
4B_E171_F 3E-06 1E-05 0.28
ASP8_E474_F 2E-10 2E-09 0.31
DK10_P199_R 0.0332 0.0332 0.1
EACAM1_E57_R 4E-13 2E-11 0.32
EACAM1_P44_R 1E-06 6E-06 0.29
LDN4_P1120_R 5E-06 1E-05 0.27
DR1_P332_R 2E-09 2E-08 0.42
LC1_E276_F 5E-08 3E-07 0.25
LC1_P88_R 0.0002 0.0003 0.18
SG1_P159_R 1E-10 2E-09 0.3
RG_E28_F 2E-08 1E-07 0.24
GF2_P229_F 0.0162 0.0188 0.13
FAP_P56_R 0.0006 0.0009 0.16
PC3_P235_R 0.0325 0.0332 0.11
DAC1_P414_R 7E-11 2E-09 0.36
OXA11_E35_F 3E-05 6E-05 0.21
OXA5_P479_F 3E-05 7E-05 0.2
GF1_P933_F 0.0307 0.0329 0.11
L1RN_E42_F 0.0005 0.0008 0.18
IG3_P622_R 2E-07 1E-06 0.26
AP3K1_P7_F 8E-09 6E-08 0.25
SH2_P1008_F 0.0241 0.0271 0.12
GFR_E328_F 0.0003 0.0005 0.17
SM_P34_F 8E-06 2E-05 0.25
ARP1_P610_R 0.0009 0.0013 0.16
DGFRB_E195_R 0.0289 0.0318 0.11
SCA_P135_F 0.0006 0.001 0.19
TPN6_P282_R 0.0009 0.0013 0.17
TPRH_E173_F 0.0138 0.0164 0.13
IPK1_P744_R 6E-05 0.0001 0.18
LC22A18_P216_R 3E-06 9E-06 0.23
NCG_P98_R 0.005 0.0063 0.14
TK11_P295_R 0.0327 0.0332 0.11
RIM29_E189_F 0.0003 0.0005 0.18
AMP8_E7_F 0.0006 0.0009 0.17
AMP8_P114_F 2E-06 8E-06 0.22
P3_P220_F 0.0005 0.0009 0.18ce
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AJP July 2011, Vol. 179, No. 1the statistical significance of any given target for associ-
ation with aggressive cancer biological features. There-
fore, MDI targets were individually tested by analysis of
variance P values and FDR-based Q scores for signifi-
cant differences between short- and long-survival ER
patient groups (Table 3). Indeed, 70% of MDI_109 tar-
gets are significantly different, and 80% of the top 50
analysis of variance–derived targets were identified
through MDI analysis.
Returning to ER cancers, we identified no significant
association between MDI and survival status (Figure 2B,
P  0.263). There was no difference in MDI between
basallike and nonbasallike ER cancers (P  0.4). In
addition, as previously noted, failure to exclude ER can-
cers from evaluation of MDI as a prognostic marker under-
mines the performance of MDI-based prognosis; this result
can be explained by the combination of significantly lower
MDI in ER cancers and the lack of correlation in that groupof MDI with survival. Because the ER cancers were pre-
dominantly of intermediate to high histological grade, we
could not effectively compare low- with high-grade ER
cancers for MDI status. However, high-grade ER cancers
have even lower MDI than low–Nottingham histological
grade/long-survival ER cancers (Figure 2B).
Next, MDI was tested for independent significance in a
multivariate regression analysis of ER cancer survival.
The univariate analysis identified the following variables
to be significantly associated with survival (P  0.05):
cancer stage, MDI_109, histological grade, MI_44 (see
later), and Her-2 amplification (Table 2). The Ki-67 index
was borderline significant (P  0.064). In the multivariate
analysis of significant variables from the univariate anal-
ysis, MDI_109 and clinical stage retained independent
significance (Table 2).
Next, we investigated the biological logic of target
methylation reprogramming in breast cancer by testing
Figure 4. Deconstruction of cancer tissue lym-
phoid and mesenchymal constituents. A: Hierar-
chical cluster of TDLU (n  32) and female-only
lymph node samples (n  9) using 59 lymphoid
tissue–specific methylation targets (seeMaterials
and Methods for LI_59 rule). B: Summary statis-
tics (box plot graph) showing the similarity of
the ER and ER groups for the LI; red spheres
denote ER cancer outliers with exceptionally
high LI and histological features of medullary
carcinoma. C: Representative photomicrograph
from high-LI outlier ER cancer showing histo-
logical features of the medullary subtype of
breast carcinoma. D: Hierarchical cluster of
TDLU (n  32) and female-only mesenchymal
samples (n  5) using 44 mesenchymal tissue–
specific methylation targets. E: Summary statis-
tics (box plot) showing the similarity of ER and
ER groups for MI. F: Photomicrograph from the
highest MI cancer case, showing histologically
pronounced mesenchymal stroma. G: ROC
curves indicate MI has prognostic value in ER
breast cancer prognosis and is anticorrelated to
disease distant recurrence. By contrast, LI has
minimal prognostic value. LI was also not signif-
icant for ER survival (P  0.2, ROC curve not
shown). A within figure indicates AUC. H: The
Kaplan-Meier curve shows longer survival time
to distant recurrence in MI-high ER cancers.
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AJP July 2011, Vol. 179, No. 1MDI targets for enrichment of certain biological annota-
tions, including CpG islands (CGIs), polycomb group
targets (PGCTs), and estrogen-responsive genes. There
was no specific targeting of CGI because more than one
third of MDI targets are off island and there is no enrich-
ment for cancer CGI versus non-CGI methylation when
adjusted for proportions of CGI and non-CGI array tar-
gets in the TDLU epigenomic space available for de novo
methylation. This result is reminiscent of our finding in
follicular lymphoma that CGIs are not specifically tar-
geted for methylation relative to non-CGIs.8 PGCTs were
significantly enriched among MDI targets: 43% of
MDI_109 are PGCTs, as defined by single occupancy of
SUZ12, EED, or H3K27me3 in human embryonic stem
cells,7,26 whereas 22% of all array targets are PGCTs.
Thus, we observed a significant moderate twofold enrich-
ment for polycomb group targets (P 10E6). Regarding
methylation reprogramming of estrogen-responsive
genes, we measured the overlap of the MDI_109 with the
published whole-genome ER- binding site cartograph of
Lin et al.27 Interestingly, there is only a single gene com-
mon to MDI_109 targets and the 234 estrogen-respon-
sive genes that neighbor estrogen response elements, as
derived from MCF-7 ChIP-Seq data. This indicates that
the methylated targets in breast cancer tissues are not
the estrogen-responsive genes in MCF-7 cells.
Next, we investigated whether group MDI differences
are substantially affected by heterogeneity for benign
tissue–specific epigenetic markers (eg, because of the
presence of tumor-infiltrating lymphoid cells or mesen-chymal cells). The LIs and MIs (ie, LI_59 and MI_44,
respectively) were calculated from array data (see Mate-
rials and Methods and Table 4). The overlap of MDI_109
with LI_59 or MI_44 is only two and three targets, respec-
tively, indicating MDI is largely not measuring lymphoid
and mesenchymal background.
Regarding possible dilutional hypodeviation among
ER cancers, we tested whether lymphoid and/or mes-
enchymal cells in that group suppress the measurement
of deviant methylation relative to the ER group. A few
outliers with notably high LI were identified in the ER
group (Figure 4B), and a review of the histological fea-
tures revealed characteristic features of the lymphoid-
rich medullary carcinoma variant28,29 (Figure 4C). Except
for these relatively rare medullary cancers,18,28,29 the
difference of LI means between ER and ER cancer LIs
is0.02 and cannot account for the significant difference
in MDI (Figure 4B). Similarly, the difference in mean MI
between ER and ER cancers was 0.02 (Figure 4E).
Thus, background tissue-specific epialleles in breast
cancers do not explain ER cancer MDI suppression or
ER cancer MDI elevation; contrasting epigenomic re-
programming is likely an intrinsic property of the breast
malignant epithelial cell genome.
Although differences of LI and MI between the ER
and ER groups do not account for MDI differences,
there is heterogeneity of LI and MI within these groups
(Figure 4, B and E); therefore, we looked for possible
correlations of LI or MI with survival. Interestingly, among
ER tumors, a high MI associates with longer survival
Figure 5. Conservation of the methylation pro-
file among primary breast cancers and their me-
tastases. A: A hierarchical cluster of eight
matched primary metastasis (P/M)–tumor pairs
(targets filtered for variance only) reveals con-
servation of the primary methylation signature in
its metastasis. Barbells link matched primary tu-
mors and metastasis. B: Representative photomi-
crographs of a matched primary tumor–metasta-
sis tumor pair, in this case showing the primary
breast carcinoma (top) and distant scalp metas-
tasis (bottom). C: Summary statistics of conser-
vation of MDI in primary tumors and metastases
(Mets). ERS indicates ER status.
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AJP July 2011, Vol. 179, No. 1(Figure 4H). Specifically, the ROC AUC for MI_44 prog-
nostic performance is 0.31 (P  0.001), indicating a fairly
robust anticorrelation of MI with subsequent distant re-
currence. Moreover, when ER cancers are divided
evenly into MI-low and MI-high groups, the Kaplan-Meier
curves show a significant difference between MI-low and
MI-high time to distant recurrence (Figure 4). Consistent
with this finding, recently, an increased histological mes-
enchymal component was determined to be a favorable
breast cancer prognostic marker.30 Among ER cancers,
LI was not significantly different between short- and long-
survival classes (P  0.2); this result will be further dis-
cussed.
Finally, we compared breast carcinoma distant metas-
tases with primary tumors for conservation of these epig-
enomic distinctions (Figure 5). Comparisons included the
following: i) eight matched pairs of primary tumors and
their metastases, ii) 23 ER metastases and 39 ER
primary tumors with subsequent distant recurrence, and
iii) four ER metastases and 19 ER primary tumors with
subsequent distant recurrence. First, in hierarchical clus-
tering of the matched pairs of primary and metastatic
lesions (Figure 5, A and B), seven of eight pairs coseg-
regate, whereas the eighth pair is slightly less similar,
indicating epigenomic stability overall. Second, the me-
dian MDI_109 values of the ER primary tumors and
metastases are 0.13 and 0.11, respectively, whereas
those of the ER cancers are 0.39 and 0.44, respectively
(Figure 5C). These findings suggest that the bulk of meth-
ylation reprogramming may occur early during tumori-
genesis, particularly in ER cancers. Although the MDI is
moderately greater in ER metastases than primary car-
cinomas (Figure 5C), we find little evidence for a con-
certed process of progression-target methylation subse-
quent to primary tumorigenesis because only two CpG
targets were significant between these two cancer
groups (data not shown). In sum, much ER breast can-
cer prognosis-related genomic methylation reprogram-
ming is already established in primary lesions and re-
mains stable through progression.
Discussion
The main finding in this study is that a genomic index of
deviant DNA methylation (ie, the MDI) is readily measur-
able from routine FFPE breast pathology samples and
correlates with aggressive cancer biological features, in-
cluding time to distant recurrence. MDI is informative to
estimate disease prognosis for ER primary invasive car-
cinomas. More important, we found that deviant methyl-
ation must be measured relative to TDLU baseline for
optimal prognostic performance. Prior studies3–6 have
also observed correlation of breast cancer clinical fea-
tures with methylation status of gene targets. In accord
with prior studies,31,32 we identified several reported
markers of ER breast cancer prognosis. These markers
include CCND2, APC, and RASSF1. Notably, the latter
two genes were detectable in the serum of patients with
breast cancer and carried prognostic significance.31One recent analysis of candidate gene expression sub-types of breast cancer1,33 noted higher methylation levels
in samples classified as luminal B versus luminal A and
basal.4 Interestingly, we found in our study that nearly
60% of reported basal-type methylation markers are con-
sistent with tissue-specific lymphoid markers and could
derive from tumor-infiltrating lymphocytes (data not
shown).
Going beyond prior studies, we observe global epig-
enomic remodeling in breast cancer, suggesting that
perhaps hundreds of robust methylation biomarkers of
ER disease prognosis are readily accessible in routine
breast biopsy specimens. Furthermore, our computation
of a TDLU baseline reference from numerous individuals
and quantification of methylation array–based lymphoid
and MIs constitute additional advances over prior stud-
ies. We found that epigenomic array-based quantification
of nonepithelial constituents, such as mesenchymal
background within ER breast carcinoma lesions, may
have prognostic value. In addition, among ER cancers,
we found no difference in LI between survival classes.
This result is in accord with recent work by Teschendorff
et al34 that suggests the prosurvival immune response
gene expression signature (“IR”) among ER cancers
derives intrinsic to the cancer epithelial cells and is not
because of extrinsic LI.
Given the many samples and the convincing prognos-
tic signal achieved in this study, global methylation pro-
filing of FFPE samples from clinical trial samples is war-
ranted to validate these findings and further pursue
predictive methyl biomarkers for a therapeutic response,
such as adjuvant chemotherapy in the treatment of ER
cancers.
Beyond these diagnostic ramifications, this study indi-
cates a fundamentally different process of epigenomic
remodeling between ER and ER cancers. Curiously,
the ER cancers have the least globally deviant methyl-
ome because their biological features may be consid-
ered to deviate the most from TDLU. For instance, ER
cancers are among the most metastatic and least hor-
monally responsive, whereas TDLU epithelial cell prolif-
eration is localized and under hormonal regulation. Fi-
nally, the observed conservation of primary tumor
methylation patterns in subsequent metastases further
underlines the biological distinction between ER and
ER groups and indicates the potential utility of methyl-
ation profiling at multiple stages of disease evolution.
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